Save up -80% on Ponatinib
Note: this is a drug discount program, not an insurance plan.
2018 Price of Iclusig
30 tablets (15mg)
* price without discount in nearest pharmacy. Price may vary.
We offer free Ponatinib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Ponatinib every time. What are you waiting for? Claim your prescription drug card now!
Ponatinib volume of distribution
After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the steady state volume of distribution is 1223 L. Ponatinib is a weak substrate for P-gp and ABCG2.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Ponatinib
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Ponatinib mechanism of action
Ponatinib is a multi-target kinase inhibitor. Its primary cellular target is the Bcr-Abl tyrosine kinase protein which is constitutively active and promotes the progression of CML. This protein arises from the fused Bcr and Abl gene- what is commonly known as the Philadelphia chromosome. Ponatinib is unique in that it is especially useful in the treatment of resistant CML because it inhibits the tyrosine kinase activity of Abl and T315I mutant kinases. The T315I mutation confers resistance in cells as it prevents other Bcr-Abl inhibitors from binding to the Abl kinase. Other targets that ponatinib inhibits are members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. A decrease in tumour size expressing native or T315I mutant BCR-ABL have been observed in rats.
Dosage forms of Ponatinib
AP 24534 AP24534
Ariad Pharmaceuticals Inc
Humans and other mammals
Indication of Ponatinib
Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
Toxicity of Ponatinib
The most common non-hematologic adverse reactions ( 20%) were hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, arthralgia, nausea, and pyrexia. Hematologic adverse reactions included thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia.
RX24 Drugs Disclaimer: before buying a Ponatinib on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.